Drug Trial Radar · NCT06608901
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
May 5, 2025
Primary completion
Feb 1, 2026
Study completion Apr 28, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Sep 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis. The aim of the study is to see how safe, tolerable, and effective the study drug is by observing the effects on blood pressure and the total amount of vasopressor dose received during the stay in the hospital. The study is looking at several other research questions, including: * How the study drug changes the blood pressure and the amount of intravenous (IV) fluids given to participants with low blood pressure due to sepsis * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions
- Sepsis-Induced Hypotension
Interventions
REGN7544Drug
Administered per the protocol
PBDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative vasopressor doseTime frame: Through 72 Hours
Locations
29 sites in 2 countries. Site status is shown where the registry gives one.
University of Arizona
Tucson, Arizona
Yale University
New Haven, Connecticut
Emory University Hospital
Atlanta, Georgia
Johns Hopkins Hospital
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Harvard Medical School - Beth Israel Deaconess Medical Center
Boston, Massachusetts
New York University Langone Health Brooklyn Hospital
Brooklyn, New York
Bellevue Hospital
New York, New York
New York University Langone Health Tisch-Kimmel Hospital
New York, New York
Montefiore Medical Center - Weiler Hospital
The Bronx, New York
Montefiore Medical Center - Moses Campus
The Bronx, New York
Atrium Health
Winston-Salem, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
MUSC SCTR Research Nexus Clinic and Lab
Charleston, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Intermountain Medical Center - Murray (Pulmonary Medicine)
Murray, Utah
Centre Hospitalier Universitaire Angers
Angers, France
Raymond Poincare University Hospital
Garches, France
Paris-Saclay University Hospitals
Le Kremlin-Bicêtre, France
CHU Nantes
Nantes, France
Centre Hospitalier Universitaire d'Orleans
Orléans, France
CHU de Reims Hopital Robert Debre
Reims, France
Hopitaux Universitaires de Strasbourg
Strasbourg, France
Hopital Nord Franche Comte
Trévenans, France
Centre Hospitalier Regional Universaitaire de Tours (CHRU de Tours)
Tours, Centre-Val de Loire, France
Hopital Cochin
Paris, Île-de-France Region, France
CHU Dupuytren
Limoges, New Aquitaine, France
Centre Hospitalier Le Mans
Le Mans, Pays de la Loire Region, France
Centre Hospitalier Departemental (CHD) Vendee
La Roche-sur-Yon, Vendee, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.